Florfenicol in aquaculture: environmental fate of residues and dissemination of antimicrobial resistance genes
Thangapalam Jawahar Abraham , Avishek Bardhan
Animal Diseases ›› 2026, Vol. 6 ›› Issue (1) : 15
Florfenicol (FFC) has become a significant antibiotic in the global aquaculture industry, particularly in the treatment of bacterial infections in finfish and shellfish. FFC is valued for its broad-spectrum bacteriostatic activity and effectiveness. This comprehensive review consolidates and expands upon existing research, offering in-depth information on FFC application across various aquaculture practices. This review addresses the key pharmacokinetic aspects of FFC, such as its absorption, distribution, metabolism, and excretion, in aquatic species. Significant attention is given to the safety profile of FFC, with discussions on residue accumulation, elimination dynamics, and the established withdrawal periods necessary to ensure consumer safety. Furthermore, this review highlights emerging issues related to FFC in aquaculture, particularly with respect to plasmid-mediated resistance, the dispersal of resistant bacteria and resistance genes, and their impact on the aquatic environment and nontarget organisms, laying a foundation for future research in this critical area. This evaluative assessment offers a novel contribution to the field, serving as an essential reference for ongoing and future studies on the appropriate use and prevention of FFC resistance in aquatic animal medicine.
Amphenicols / Pharmacokinetics / Antibiotic residues / Residue distribution / Resistance genes
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
Armstrong, S.M., B.T. Hargrave, and K. Haya. 2005. Antibiotic use in finfish aquaculture: modes of action, environmental fate, and microbial resistance. In Environmental effects of marine finfish aquaculture. Handbook of environmental chemistry, vol 5 M, ed. B.T. Hargrave, 341–357. Berlin, Heidelberg: Springer. https://doi.org/10.1007/b136017 |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Burridge, L. and A. Holmes. 2023. An updated review of hazards associated with the use of pesticides and drugs used in the marine environment by the finfish aquaculture industry in Canada. Fisheries and Oceans Canada, Canadian Science Advisory Secretariat Research Document 2022/067. iv + 38p Ottawa, Canada. http://www.dfo-mpo.gc.ca/csas-sccs/csas-sccs@dfo-mpo.gc.ca. |
| [18] |
|
| [19] |
CA. 2024. Maximum residue limits (MRLs) and risk management in recommendations (RMRs) for residues of veterinary drugs in foods. CXM 2024. Codex Alimentarius International Food Standards. FAO and WHO. https://www.fao.org/fao-who-codexalimentarius/sh-proxy/hu/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXM%2B2%252FMRL2e.pdf. |
| [20] |
CFIA. 2017. Aquaculture Therapeutant Residue Monitoring List. Canadian Food Inspection Agency. Canada. Retrieved from CFIA: http://www.inspection.gc.ca/food/fish-and-seafood/manuals/standards-and-methods/eng/1348608971859/1348609209602?chap= 7#s17c7. |
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
EMA. 2018. Questions and Answers: Implementation of EMA guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 (Phase I) and GL38 (Phase II). Committee for Medicinal Products for Veterinary Use, EMEA/EMA/ERA/172074/2008-Rev.6, London, United Kingdom. https://www.ema.europa.eu/en/documents/other/questions-and-answers-implementation-cvmp-guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-phase-i-and-gl38-phase-ii_en.pdf. |
| [30] |
EMA. 2025. European sales and use of antimicrobials for veterinary medicine (ESUAvet). Annual surveillance report for 2023. EMA/CVMP/ESUAVET/80289/2025. https://www.ema.europa.eu/en/documents/report/european-sales-use-antimicrobials-veterinary-medicine-annual-surveillance-report-2023_en.pdf |
| [31] |
EMA/CMDv. 2023. Veterinary Medicinal Products Intended for Fish. EMA/CMDv/650880/2018. https://www.hma.eu/veterinary-medicines/cmdv/procedural-guidance/miscellaneous.html. |
| [32] |
|
| [33] |
FAO. 2024. The State of World Fisheries and Aquaculture 2024. Blue transformation in action. Food and Agriculture Organization, Rome. https://doi.org/10.4060/cd0683en. |
| [34] |
FDA, 2013. Environmental assessment for Aquaflor (florfenicol). Aquaflor for freshwater-reared finfish in recirculating aquaculture systems [online] EPA. Available at: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadEA/113. |
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
Kogiannou, D., C. Nikoloudaki, P. Katharios, A. Triga, and G. Rigos. 2021. Evaluation of absorption and depletion of florfenicol in European seabass Dicentrarchus labrax. Veterinary Medicine and Science 7(3):987-997. https://doi.org/10.1002/vms3.415. |
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
Nightingale, J.H. 2022. Managing the release of emerging agricultural contaminants into the environment. PhD thesis. The University of Leeds. Woodhouse, Leeds, United Kingdom. https://etheses.whiterose.ac.uk/id/eprint/31363/ |
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
USFDA. 2025. Approved Aquaculture Drugs. United States Food and Drug Administration. https://www.fda.gov/animal-veterinary/aquaculture/approved-aquaculture-drugs Accessed 22 September 2025 |
| [137] |
USFWS. 2020. Approved Drugs for Use in Aquaculture, Third ed. U.S. Fish and Wildlife Service’s (USFWS) Aquatic Animal Drug Approval Partnership Program, American Fisheries Society’s Fish Culture and Fish Health Sections. Association of Fish and Wildlife Agencies and Fisheries and Water Resources Policy Committee’s Drug Approval Working Group. https://www.fws.gov/sites/default/files/documents/3rd-Edition-Quick-Reference-Guide-to-Approved-for-Use-in-Aquaculture-Drugs.pdf |
| [138] |
VICH. 2003. Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products (VMPs) - Phase II Draft Guidance. London: CVMP/VICH GL 38. CVMP/VICH/790/03-Consultation. https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl38-environmental-impact-assessments-veterinary-medicinal-products-vmps-phase-ii_en. |
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
WOAH 2021. OIE List of Antimicrobial Agents of Veterinary Importance. World Organization for Animal Health, Paris, France. https://www.woah.org/app/uploads/2021/06/a-oie-list-antimicrobials-june2021.pdf |
| [150] |
WOAH, 2024. Annual Report on Antimicrobial Agents Intended for Use in Animals. 8th Report. World Organization for Animal Health. Paris, France. p33. https://www.woah.org/app/uploads/2024/05/woah-amu-report-2024-final.pdf. |
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
The Author(s)
/
| 〈 |
|
〉 |